Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Barclays analyst Etzer Darout has maintained an Overweight rating on Iovance Biotherapeutics (NASDAQ: IOVA) and raised the price target from $15 to $18. This adjustment reflects a positive outlook for the company in the market.